ArriVent BioPharma Reports Full Year 2025 Financial Results

Core Insights - ArriVent BioPharma, Inc. is advancing its lead candidate firmonertinib towards potential registration for treating non-small cell lung cancer (NSCLC) with uncommon EGFR mutations, addressing a significant unmet medical need [2][3] - The company reported a cash position of $312.8 million as of December 31, 2025, which is expected to fund operations into the third quarter of 2027 [5][8] - The company is also developing an antibody-drug conjugate (ADC) portfolio, with ARR-217 currently in a Phase 1 trial for gastrointestinal cancers [2][4] Recent and Full Year 2025 Highlights - Firmonertinib is being evaluated in pivotal Phase 3 studies for first-line treatment of NSCLC with EGFR exon 20 insertion mutations and PACC mutations, with topline data expected in mid-2026 [5][12] - Positive final data from the Phase 1b FURTHER trial showed firmonertinib's potential in patients with EGFR PACC mutations, demonstrating clinically meaningful progression-free survival and CNS responses [6][12] - The company completed enrollment for the pivotal FURVENT trial in early 2025, which assesses firmonertinib against platinum-based chemotherapy [6][16] Financial Results - For the year ended December 31, 2025, the company reported a net loss of $166.3 million, compared to a net loss of $80.5 million in 2024 [21] - Research and development expenses increased to $153.4 million in 2025 from $79.0 million in 2024, reflecting investments in clinical trials [21] - General and administrative expenses rose to $24.2 million in 2025 from $15.3 million in 2024 [21] Pipeline Developments - The ADC candidate ARR-217 is in an ongoing Phase 1 trial, with plans to expand the pipeline into multiple solid tumor indications [2][4] - The company plans to file an Investigational New Drug (IND) application for a first-in-class ADC program in the first half of 2026 [13] - Completion of Phase 1 dose escalation for ARR-217 is anticipated in the second half of 2026 [13] Upcoming Milestones - Topline data for firmonertinib in the pivotal FURVENT study is projected for mid-2026 [5][12] - The company aims to present preclinical data for its ADC programs at an upcoming conference [13]